Friday, 17 Aug 2018

PsA/SpA

Datesort ascending Type Title Save
13 Jun 2018 Social RT @DrPetryna: #EULAR18 @RheumNow ABST op0067 Increased Dickkopf-1 (DKK1)( a natural inhibitor of Wnt signalling pathway) associated with d…
13 Jun 2018 Social Lindstrom studied their Swedish AS registry and found that While the presence of Uveitis was assoc w/ better TNFi responses; all other comorbidities yielded lesser TNFi responses. #EULAR2018 @RheumNow OP0023 https://t.co/bltRC4khbL
13 Jun 2018 Social RT @DrPetryna: #EULAR18 @RheumNow ABST op0028 BCD-085, novel humanised monoclonal IL-17 Ab w/ genetically modified Fc- and CDR-regions sho…
02 Jun 2018 Social RheumNow Wk in Review is up. Good news for GPA and Renal transplant, Early RA challenges, Vaccinots and HPV and the risk of cancer in PsA. Check out the podcast https://t.co/nqif5yPBx9 or the website video https://t.co/bj6ar7ZlYT
31 May 2018 News MRI Imaging for Sacroiliitis Requires Bone Marrow Edema for Reliability
29 May 2018 Social UCB announces the FDA has approved Cimzia (certolizumab) for use in moderate to severe plaque psoriasis based on over 1000 pts in Phase 3 RCTs CIMPASI-1, CIMPASI-2 and CIMPACT and PASI75 of 75-82% at wk16 https://t.co/PYx15htd3Z
29 May 2018 Social Certolizumab is now FDA approved for use in Crohns disease, Rheumatoid arthritis, Ankylosing spondylitis, psoriatic arthritis and now Psoriasis.https://t.co/QVpmv7V9PI
29 May 2018 News Cancer Risk Raised in Psoriatic Arthritis
17 May 2018 News Trends in Psoriatic Arthritis Treatment 2004-2015
14 May 2018 News Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors
14 May 2018 Slide of the day Rare Risk of Colitis with IL-17 Inhibitors
13 May 2018 Social RT @NatRevRheumatol: Our new #Review is online! Gladman and colleagues highlight the similarities and differences between #AnkylosingSpondy…
03 May 2018 News Targeting IL-17A: A Winner in PsA
01 May 2018 News Comorbidities Undermine Clinical Outcomes in Psoriatic Arthritis
30 Apr 2018 Social April meeting of European Medicines Agency, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of new indications for CIMZIA- certolizumab pegol (for plaque psoriasis) and XELJANZ-tofacitinib (for psoriatic arthritis). https://t.co/W4A0AIyZ80
19 Apr 2018 Social RT @LCalabreseDO: Anxiously await PHASE 3 Tocilizumab PSS study. The extension is provocative. Toxicity will be key based on effect size ht…
10 Apr 2018 News Apremilast in DMARD-Naive Psoriatic Arthritis
07 Apr 2018 Social RT @emartinmola: Most PsA patients discontinue initial biologic within 12 months https://t.co/KxfWR4IsNn
04 Apr 2018 Social Study of 114 kids with enthesitis related JIA shows axial Dz/sacroiliitis rare at onset but after mean of 2.6 yrs found in 63% and 47% respectively. + Familiy Hx of SpA associated w/ sacroiliitis (OR = 3.6) & active disease (OR 3.0) at last FUV https://t.co/xRQhm6iGA6
03 Apr 2018 Blog The Delayed Diagnosis of Spondyloarthritis